Isofol Medical AB (publ)
STO: ISOFOL.ST0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Stockholm Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Petter Segelman Lindqvist
- Employees
- 5
- Headquarters
- Gothenburg, Sweden
- IPO year
- 2017
- Market cap
- SEK 223.1M
- Website
- https://isofolmedical.com
Loading ISOFOL…
Loading profile data…Frequently asked questions about ISOFOL
What does Isofol Medical AB (publ) (ISOFOL.ST) do?
Isofol Medical AB (publ), a clinical stage biotech company, develops, commercializes, and sells oncology drugs in Sweden and internationally. The company develops arfolitixorin, which is in phase 3 clinical trial for the treatment of advanced colorectal cancer. It has strategic collaborations with Recipharm, Merck & Cie, and Sahlgrenska Universi...
Where does ISOFOL.ST trade?
Isofol Medical AB (publ) (ISOFOL.ST) trades on the Stockholm Stock Exchange.
What sector is ISOFOL.ST in?
Isofol Medical AB (publ) (ISOFOL.ST) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Isofol Medical AB (publ)?
Petter Segelman Lindqvist is the chief executive officer of Isofol Medical AB (publ) (ISOFOL.ST).
Where is Isofol Medical AB (publ) headquartered?
Isofol Medical AB (publ) is headquartered in Sweden.
Does ISOFOL.ST pay a dividend?
Isofol Medical AB (publ) (ISOFOL.ST) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did ISOFOL.ST go public?
Isofol Medical AB (publ) (ISOFOL.ST) completed its initial public offering in 2017.